Answers are grounded in this paper and cite their sources.
Clinical case review evaluates management strategies in fulminant Clostridioides difficile infection, highlighting divergent guideline recommendations on fecal transplantation and bezlotoxumab.
The Infectious Diseases Society of America/Society for Healthcare Epidemiology of America and the American College of Gastroenterology recently released updated guidelines on management of patients with Clostridioides difficile infection. Although these 2 guidelines generally agree, there are a few important differences in their advice to clinicians. In these rounds, 2 experts, an infectious diseases specialist and a gastroenterologist, discuss antibiotic treatment options for nonsevere disease, the role of fecal microbiota transplantation for fulminant disease, and the use of bezlotoxumab to prevent recurrence in the context of Ms. C, a 48-year-old woman with fulminant C difficile infection.
No takes yet. Share an insight, caveat, or question.
Kanjee et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: